Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.73 |
| ▸ | RAB9A | P51151 | 5/20 | 0.73 |
| ▸ | TP53 | P04637 | 3/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.73 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.73 |
| ▸ | HTT | P42858 | 1/20 | 0.73 |
| ▸ | MAPT | P10636 | 10/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.63 |
| ▸ | GLA | P06280 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | CA12 | O43570 | 1/20 | 0.60 |
| ▸ | CA1 | P00915 | 1/20 | 0.60 |
| ▸ | CA2 | P00918 | 1/20 | 0.60 |
| ▸ | CA9 | Q16790 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18938519 | 0.89 | NPC1 (0.77) | NPC1RAB9ATP53SMN1; SMN2MAPK1 | |
| SCHEMBL5183604 | 0.88 | NPC1 (0.64) | NPC1RAB9ATP53SMN1; SMN2MAPK1 | |
| SCHEMBL5184734 | 0.88 | NPC1 (0.64) | NPC1RAB9ATP53SMN1; SMN2MAPK1 | |
| SCHEMBL5183437 | 0.86 | NPC1 (0.62) | NPC1RAB9ATP53SMN1; SMN2MAPK1 | |
| SCHEMBL5184503 | 0.86 | KMT2A (0.75) | NPC1RAB9ATP53SMN1; SMN2MAPK1 | |
| SCHEMBL18938397 | 0.86 | NPC1 (0.77) | NPC1RAB9ATP53SMN1; SMN2MAPK1 | |
| SCHEMBL3061178 | 0.85 | NPC1 (0.78) | NPC1RAB9ATP53SMN1; SMN2MAPK1 | |
| SCHEMBL18470910 | 0.85 | RAB9A (1.00) | NPC1RAB9ATP53SMN1; SMN2MAPK1 | |
| SCHEMBL3142490 | 0.85 | RAB9A (1.00) | NPC1RAB9ATP53SMN1; SMN2MAPK1 | |
| SCHEMBL632109 | 0.84 | CA12 (0.69) | TP53SMN1; SMN2MAPK1ALOX15HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295133-A1 | PROCESS FOR PREPARING A COMPOUND USEFUL TO TREAT MYCOSES | PULMOCIDE LIMITED (GB) | 2023-09-21 | — | — | US | disclosed |
| US-11661415-B2 | Process for preparing a compound useful to treat mycoses | PULMOCIDE LIMITED (GB) | 2023-05-30 | — | — | US | disclosed |
| US-20210238169-A1 | PROCESS FOR PREPARING A COMPOUND OF FORMULA (XIII) | PULMOCIDE LIMITED (GB) | 2021-08-05 | — | — | US | disclosed |
| US-11008307-B2 | Compounds which are used in the preparation of the compound of formula (I) | PULMOCIDE LIMITED (GB) | 2021-05-18 | — | — | US | disclosed |
| US-20210048874-A1 | PROCESS FOR PREPARING A COMPOUND USEFUL TO TREAT MYCOSES | PULMOCIDE LIMITED (GB) | 2021-02-18 | — | — | US | disclosed |
| US-20200399253-A1 | COMPOUNDS WHICH ARE USED IN THE PREPARATION OF THE COMPOUND OF FORMULA (I) | PULMOCIDE LIMITED (GB) | 2020-12-24 | — | — | US | disclosed |
| US-10858345-B2 | Process for preparing a compound useful to treat mycoses | PULMOCIDE LIMITED (GB) | 2020-12-08 | — | — | US | disclosed |
| US-10800762-B2 | Compounds which are used in the preparation of the compound of formula (II) | PULMOCIDE LIMITED (GB) | 2020-10-13 | — | — | US | disclosed |
| US-20200239453-A1 | PROCESS FOR PREPARING A COMPOUND USEFUL TO TREAT MYCOSES | PULMOCIDE LIMITED (GB) | 2020-07-30 | — | — | US | disclosed |
| US-10662179-B2 | Process for preparing a compound useful to treat mycoses | PULMOCIDE LIMITED (GB) | 2020-05-26 | — | — | US | disclosed |
| US-20190023697-A1 | Antimycotic compound | PULMOCIDE LIMITED (GB) | 2019-01-24 | — | — | US | disclosed |
| US-20190023696-A1 | COMPOUND | PULMOCIDE LIMITED (GB) | 2019-01-24 | — | — | US | disclosed |
| US-10106531-B2 | Compound useful to treat mycoses | PULMOCIDE LIMITED (GB) | 2018-10-23 | — | — | US | disclosed |
| US-10093659-B2 | Compound useful to treat mycoses | PLUMOCIDE LIMITED (GB) | 2018-10-09 | — | — | US | disclosed |
| US-20170320858-A1 | COMPOUND | PULMOCIDE LIMITED (GB) | 2017-11-09 | — | — | US | disclosed |
| EP-3227278-A1 | ANTIMYCOTIC COMPOUND | Pulmocide Limited (GB) | 2017-10-11 | — | — | EP | disclosed |
| EP-3227277-A1 | ANTIMYCOTIC COMPOUND | Pulmocide Limited (GB) | 2017-10-11 | — | — | EP | disclosed |
| US-20170037035-A1 | COMPOUND | PULMOCIDE LIMITED (GB) | 2017-02-09 | — | — | US | disclosed |
| WO-2016087880-A1 | ANTIMYCOTIC COMPOUND | PULMOCIDE LIMITED (GB) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016087878-A1 | ANTIMYCOTIC COMPOUND | PULMOCIDE LIMITED (GB) | 2016-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320858-A1 | COMPOUND | MYC, DPM1, ERG28 | NPC1 405/4885RAB9A 3472/4885TP53 997/4885 |
| US-20190023696-A1 | COMPOUND | DPM1, MYC, ERG28 | NPC1 316/4885RAB9A 3538/4885TP53 1004/4885 |
| US-10093659-B2 | Compound useful to treat mycoses | DPM1, MYC, ERG28 | NPC1 325/4885RAB9A 3139/4885TP53 803/4885 |
| US-20200399253-A1 | COMPOUNDS WHICH ARE USED IN THE PREPARATION OF THE COMPOUND OF FORMULA (I) | CYP11B2, CYP11B1, CYP21A2 | NPC1 141/4885RAB9A 2502/4885TP53 3684/4885 |
| US-10106531-B2 | Compound useful to treat mycoses | DPM1, ERG28, MYC | NPC1 390/4885RAB9A 2872/4885TP53 868/4885 |
| US-10662179-B2 | Process for preparing a compound useful to treat mycoses | ERG28, DPM1, CYP51A1 | NPC1 226/4885RAB9A 2224/4885TP53 790/4885 |
| US-11008307-B2 | Compounds which are used in the preparation of the compound of formula (I) | CYP11B2, CYP11B1, CYP21A2 | NPC1 141/4885RAB9A 2502/4885TP53 3684/4885 |
| US-20190023697-A1 | Antimycotic compound | DPM1, MYC, ERG28 | NPC1 577/4885RAB9A 3568/4885TP53 1155/4885 |
| US-10800762-B2 | Compounds which are used in the preparation of the compound of formula (II) | CYP11B2, SDHB, SDHA | NPC1 267/4885RAB9A 2298/4885TP53 3227/4885 |
| US-20200239453-A1 | PROCESS FOR PREPARING A COMPOUND USEFUL TO TREAT MYCOSES | ERG28, DPM1, CYP51A1 | NPC1 226/4885RAB9A 2224/4885TP53 790/4885 |
| US-10858345-B2 | Process for preparing a compound useful to treat mycoses | DPM1, CYP51A1, ERG28 | NPC1 713/4885RAB9A 1450/4885TP53 1098/4885 |
| US-11661415-B2 | Process for preparing a compound useful to treat mycoses | DPM1, CYP51A1, ERG28 | NPC1 713/4885RAB9A 1450/4885TP53 1098/4885 |
| US-20230295133-A1 | PROCESS FOR PREPARING A COMPOUND USEFUL TO TREAT MYCOSES | DPM1, CYP51A1, ERG28 | NPC1 713/4885RAB9A 1450/4885TP53 1098/4885 |
| US-20210238169-A1 | PROCESS FOR PREPARING A COMPOUND OF FORMULA (XIII) | CYP2F1, CYP4A11, CYP4F11 | NPC1 752/4885RAB9A 1121/4885TP53 4433/4885 |
| US-20170037035-A1 | COMPOUND | DPM1, MYC, ERG28 | NPC1 316/4885RAB9A 3538/4885TP53 1004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.